In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will acquire treatment until eventually disease progression or the participants are unable to tolerate the study drugs. - "Our study unveiled the essential function of your KLF16/MYC regulatory axis in https://clinicaleffectivenessofab91346.onesmablog.com/clinical-trial-recruitment-for-abbv-744-study-fundamentals-explained-72518602